Figures & data
Figure 1 Combined treatment with GSK126 and Gefitinib exhibited synergic effect on survival fraction in different types of cancer cells.
![Figure 1 Combined treatment with GSK126 and Gefitinib exhibited synergic effect on survival fraction in different types of cancer cells.](/cms/asset/ee27ce34-e495-4549-8a54-e4655af4f5f5/dott_a_186498_f0001_c.jpg)
Figure 2 Combined treatment with GSK126 and Gefitinib caused enhanced apoptosis.
![Figure 2 Combined treatment with GSK126 and Gefitinib caused enhanced apoptosis.](/cms/asset/c7b3d2e5-5936-4148-a6a3-7a722a31bee5/dott_a_186498_f0002_c.jpg)
Figure 3 Combined treatment with GSK126 and Gefitinib had synergic effect on autophagy induction.
Abbreviations: 3-MA, 3-methyladenine; p-ULK, phosphorylated ULK; ULK, Unc-51-like autophagy activating kinase; t-ULK, total ULK.
![Figure 3 Combined treatment with GSK126 and Gefitinib had synergic effect on autophagy induction.](/cms/asset/d3e6ca49-d578-4bd1-9015-91811d65f660/dott_a_186498_f0003_b.jpg)
Figure 4 Combined treatment with GSK126 and Gefitinib resulted in greater inhibition of mTOR pathway.
Abbreviations: mTOR, mammalian target of rapamycin; p-mTOR, phosphorylated mTOR.
![Figure 4 Combined treatment with GSK126 and Gefitinib resulted in greater inhibition of mTOR pathway.](/cms/asset/36330222-3d6f-4236-b872-aa16cb5c3742/dott_a_186498_f0004_b.jpg)
Figure 5 Combined treatment with GSK126 and Gefitinib significantly inhibited tumor xenograft in nude mice but did not affect body weight and liver function.
Abbreviations: i.p., intraperitoneal; p-ULK, phosphorylated ULK; ULK, Unc-51-like autophagy activating kinase; ALT, alanine transaminase; AST, aspartate transaminase; t-ULK, total ULK.
![Figure 5 Combined treatment with GSK126 and Gefitinib significantly inhibited tumor xenograft in nude mice but did not affect body weight and liver function.](/cms/asset/68154d9c-e97f-44ac-8b15-14a80e230660/dott_a_186498_f0005_c.jpg)